 Zynerba Pharmaceuticals Inc has posted second-quarter results with ample cash on hand, which gives the company a long runway to run pivotal trials of its flagship product Zygel ZYN002, a patent-protected CBD skin gel, which is being developed to treat a slew of rare neuropsychiatric disorders, including Fragile X syndrome FXS and developmental and epileptic encephalopathies DEE programs. The Devon, Pennsylvania-based company had 85.8 million in cash and equivalents as of June 30, 2021, compared to 59.2 million at the end of December 2020. 